Eric Winquist
Impact in
- Otorhinolaryngology top 0.05%
- Head and Neck Cancer Studies
- Pulmonary and Respiratory Medicine top 0.2%
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
Papers in
-
- Head and Neck Cancer Studies 46
-
- Renal cell carcinoma treatment 30
- Prostate Cancer Treatment and Research 29
- Co-authors
- Sebastién J. Hotte (35 shared papers)Lillian L. Siu (14 shared papers)Malcolm J. Moore (14 shared papers)Hans von der Maase (3 shared papers)Joaquim Bellmunt (3 shared papers)Gregory R. Pond (13 shared papers)John J. Yoo (20 shared papers)Himu R. Lukka (9 shared papers)
- Journals
- Journal of Clinical Oncology (24 papers)Annals of Oncology (17 papers)International Journal of Radiation Oncology*Biology*Physics (11 papers)Investigational New Drugs (10 papers)The Journal of Urology (9 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Eric Winquist
251 papers receiving 18.1k citations
Eric Winquist's Hit Papers
Peers
Comparison fields: 5 of 146
- Otorhinolaryngology 2.7k
- Pulmonary and Respiratory Medicine 6.2k
- Oncology 4.9k
- Cancer Research 2.0k
- Surgery 4.5k
Countries citing papers authored by Eric Winquist
This map shows the geographic impact of Eric Winquist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Winquist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Winquist more than expected).
Fields of papers citing papers by Eric Winquist
This network shows the impact of papers produced by Eric Winquist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Winquist. The network helps show where Eric Winquist may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric Winquist, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 266 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy Hit paper breakdown → | 2012 | 2299 |
| 2 | Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers Hit paper breakdown → | 2008 | 1734 |
| 3 | Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer Hit paper breakdown → | 2007 | 1324 |
| 4 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Hit paper breakdown → | 2021 | 1323 |
| 5 | Exemestane for Breast-Cancer Prevention in Postmenopausal Women Hit paper breakdown → | 2011 | 770 |
| 6 | Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Hit paper breakdown → | 2009 | 611 |
| 7 | 2010 | 372 | |
| 8 | Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987 Hit paper breakdown → | 2012 | 364 |
| 9 | Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial Hit paper breakdown → | 2013 | 359 |
| 10 | Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial Hit paper breakdown → | 2019 | 355 |
| 11 | 2004 | 280 | |
| 12 | 2000 | 265 | |
| 13 | 2005 | 236 | |
| 14 | 2007 | 221 | |
| 15 | 2003 | 210 | |
| 16 | Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 210 |
| 17 | 2007 | 209 | |
| 18 | 2018 | 196 | |
| 19 | 2014 | 191 | |
| 20 | 1999 | 184 |
About Eric Winquist
Eric Winquist is a scholar working on Otorhinolaryngology, Pulmonary and Respiratory Medicine, Oncology, Surgery and Cancer Research, having authored 266 papers that have together received 18.6k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (46 papers), Renal cell carcinoma treatment (30 papers), Prostate Cancer Treatment and Research (29 papers), Bladder and Urothelial Cancer Treatments (28 papers), Testicular diseases and treatments (20 papers), Urinary and Genital Oncology Studies (11 papers), Cancer Genomics and Diagnostics (10 papers) and Cancer Diagnosis and Treatment (10 papers). The work is most often cited by research in Otorhinolaryngology (2.7k citations), Pulmonary and Respiratory Medicine (6.2k citations), Oncology (4.9k citations), Cancer Research (2.0k citations) and Surgery (4.5k citations). Eric Winquist has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Sebastién J. Hotte, Lillian L. Siu, Malcolm J. Moore, Hans von der Maase, Joaquim Bellmunt, Gregory R. Pond, John J. Yoo, Himu R. Lukka, Larry Stitt and Joseph L. Chin. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, International Journal of Radiation Oncology*Biology*Physics, Investigational New Drugs and The Journal of Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.